Calidi Biotherapeutics to Present New Data on Its Lead Asset CLD-401 at the AACR Annual Meeting in April 2026
Rhea-AI Summary
Calidi Biotherapeutics (NYSE American: CLDI) will present new preclinical data on its lead candidate CLD-401 at the American Association for Cancer Research (AACR) annual meeting, April 17-22, 2026 in San Diego.
The data will describe tumor-restricted expression of an IL-15 superagonist (IL-15 SA) by CLD-401 and resulting immune changes in the tumor microenvironment; Calidi expects to file an IND for CLD-401 by the end of 2026.
Positive
- None.
Negative
- None.
News Market Reaction – CLDI
In the Apr 2 session, CLDI declined 2.72%, reflecting a moderate negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Apr 01 | AACR data preview | Positive | +1.6% | Announced AACR data on RedTail platform and TROP2-targeting candidate. |
| Mar 27 | Earnings and update | Neutral | -11.7% | Reported 2025 results, partnerships, FDA feedback, and $6.5M capital raised. |
| Mar 24 | Clinical partnership | Positive | -3.6% | Partnered with Avance Clinical to expedite Australian approval and Phase I start. |
| Mar 12 | Manufacturing update | Positive | -4.5% | Presented scalable CLD-401 manufacturing with supportive FDA feedback. |
| Mar 09 | Equity offering | Negative | -1.5% | Closed $6.0M underwritten offering with multiple warrant series. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
CLDI’s news on CLD-401 and platform progress has often coincided with negative or muted price reactions, while dilutive offerings saw declines consistent with their negative tone.
Over the past month, Calidi has repeatedly highlighted CLD-401 and its RedTail virotherapy platform. Updates have covered strategic partnerships to start a Phase I trial, FDA Type D feedback supporting manufacturing, and presentations on scalable production, all targeting an IND filing by end of 2026. A recent $6.0M public offering and financials showing a $25.6M 2025 net loss and $5.6M cash underscore financing needs alongside scientific progress. Today’s AACR data announcement fits this ongoing CLD-401 narrative.
Key Terms
oncolytic virus medical
il-15 superagonist medical
tumor microenvironment medical
virotherapy medical
pharmacokinetic medical
cytokine medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
SAN DIEGO, April 02, 2026 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE American: CLDI) (“Calidi” or the “Company”), a biotechnology company pioneering the development of targeted genetic medicines, will present new data at the American Association of Cancer Research (AACR) annual meeting in San Diego, California from April 17-22, 2026. The Company will showcase new data on CLD-401, a systemically delivered oncolytic virus that is designed to express high levels of IL-15 superagonist (“IL-15 SA”) only in the tumor microenvironment (“TME”), currently in IND-enabling studies.
CLD-401 is the lead candidate from the Company’s RedTail platform, a systemically delivered virotherapy platform designed to selectively target tumors, remodel the TME, and enable high-level expression of therapeutic genetic payloads directly within the tumor. CLD-401 is engineered to express high levels of IL-15 SA, a known T- and NK-cell activator, in the TME. Data at AACR will detail the pattern of CLD-401 mediated-IL-15 SA expression and the subsequent immune changes in the TME, leading to a robust therapeutic response. The Company expects to file an IND for CLD-401 by the end of 2026.
“We continue to advance the RedTail platform and its breakthrough capabilities through our lead asset, CLD-401,” said Eric Poma, PhD, Chief Executive Officer of Calidi. “We expect to file an IND for CLD-401 by end of 2026 and enter the clinic shortly thereafter.”
“The data we will present at AACR will characterize the pharmacokinetic pattern of IL-15 SA expression and resulting changes in the TME” said Antonio F. Santidrian, PhD, Chief Scientific Officer and Head of Technical Operations at Calidi. “The ability of CLD-401 to induce high levels of IL15-SA expression in the TME but not systemically may dramatically alter the therapeutic window of cytokine treatment.”
The Company continues to expand the functionality of the RedTail platform and is also actively pursuing strategic partnerships to accelerate clinical development and broaden the impact of its RedTail platform.
About Calidi
Calidi Biotherapeutics (NYSE American: CLDI) is a biotechnology company pioneering the development of targeted therapies with the potential to deliver genetic medicines to distal sites of disease. The company’s proprietary RedTail platform features an engineered enveloped oncolytic virus designed for systemic delivery and targeting of metastatic sites. This advanced enveloped technology is intended to shield the virus from immune clearance, allowing virotherapy to effectively reach tumor sites, induce tumor lysis, and deliver potent genetic medicine(s) to metastatic locations.
CLD-401, the lead candidate from the RedTail platform, currently in IND-enabling studies, targets non-small cell lung cancer, head and neck cancer, and other tumor types with high unmet medical need. Calidi continues to advance its pipeline utilizing the RedTail platform including its novel approach to incorporate in situ T-cell engagers in solid tumors.
Calidi Biotherapeutics is headquartered in San Diego, California. For more information, please visit www.calidibio.com or view Calidi’s Corporate Presentation here.
Forward-Looking Statements
This press release may contain forward-looking statements for purposes of the “safe harbor” provisions under the United States Private Securities Litigation Reform Act of 1995. Terms such as “anticipates,” “believe,” “continue,” “could,” “estimate,” “expect,” “intends,” “may,” “might,” “plan,” “possible,” “potential,” “predicts,” “project,” “should,” “towards,” “would” as well as similar terms, are forward-looking in nature, but the absence of these words does not mean that a statement is not forward-looking. These forward-looking statements include, but are not limited to, statements concerning key milestones, including certain pre-clinical data, planned clinical trials, and statements relating to the safety and efficacy of Calidi’s therapeutic candidates in development. Any forward-looking statements contained in this discussion are based on Calidi’s current expectations and beliefs concerning future developments and their potential effects and are subject to multiple risks and uncertainties that could cause actual results to differ materially and adversely from those set forth or implied in such forward-looking statements. These risks and uncertainties include, but are not limited to, the risk that Calidi is not able to raise sufficient capital to support its current and anticipated clinical trials, the risk that early results of clinical trials do not necessarily predict final results and that one or more of the clinical outcomes may materially change following more comprehensive review of the data, and as more patient data becomes available, the risk that Calidi may not receive FDA approval for some or all of its therapeutic candidates. Other risks and uncertainties are set forth in the section entitled “Risk Factors” and “Cautionary Note Regarding Forward-Looking Statements” in the Company’s annual report filed with the SEC on Form 10-K on March 27, 2026, as may be amended or supplemented by other reports we file with the SEC from time to time. We disclaim any obligation to update any forward-looking statement to reflect events or circumstances after the date of this press release or to reflect the occurrence of unanticipated events.
For Investors:
Dave Gentry, CEO
RedChip Companies, Inc.
1-407-644-4256
CLDI@redchip.com
